Intraoperative Goal Directed Fluid Management in Supratentorial Brain Tumor Craniotomy

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT03033706
Collaborator
(none)
61
1
2
10.2
6

Study Details

Study Description

Brief Summary

Pulse pressure variation (PPV) to standard fluid management (4ml/Kg/hr) in patients undergoing supratentorial mass excision. The investigators hypothesize that in these procedures, goal-directed fluid therapy (GDT) might improve brain relaxation, and patient hemodynamics intra and postoperatively.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pulse pressure variation guided fluid therapy
  • Procedure: Traditional fluid therapy
  • Procedure: Brain tumor excision
N/A

Detailed Description

Neurosurgical operations are characterized by major fluid shift, frequent use of diuretics, and prolonged operative time. The role of fluid therapy in these patients is very critical, hypovolemia might lead to brain hypoperfusion and over-transfusion might lead increased intracranial tension. All these factors make fluid management in these procedures complex and challenging. Evidence on the optimum protocol for intraoperative fluid management in neurosurgical patients is still lacking.

Goal-directed therapy (GDT) in the operating room is a term used to describe the use of cardiac output or similar parameters to guide intravenous fluid and inotropic therapy.

Although GDT was well reported in many procedures, its benefit in neurosurgical operations is not well studied.

Pulse pressure variation (PPV) is a famous dynamic method of fluid responsiveness. PPV is simply calculated by dividing the largest pulse pressure (PPmax - PPmin) by the average pulse pressure (PPmax + PPmin /2) and expressed as percentage. PPV was previously used in GDT in major abdominal surgery with good performance.

The aim of this study is to compare the restricted fluid approach (1 ml/Kg/hr) guided by PPV to standard fluid management (4ml/Kg/hr) in patients undergoing supratentorial mass excision. The investigators hypothesize that in these procedures GDT might improve brain relaxation, and patient hemodynamics intra and postoperatively.

Study Design

Study Type:
Interventional
Actual Enrollment :
61 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Intraoperative Goal Directed Fluid Management Guided by Pulse Pressure Variation in Supratentorial Brain Tumor Craniotomy: a Randomized Controlled Study
Actual Study Start Date :
Mar 25, 2017
Actual Primary Completion Date :
Jan 25, 2018
Actual Study Completion Date :
Jan 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Study group

Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation guided fluid therapy): Study group will receive restricted fluid management with 1 ml/Kg/hr with concomitant PPV monitoring. PPV will be measured using invasive blood pressure monitor. Fluid bolus of 3 ml/Kg of ringer solution will be administrated whenever PPV is higher than 13%.

Procedure: Pulse pressure variation guided fluid therapy
Pulse pressure variation obtained from invasive blood pressure waveform

Procedure: Brain tumor excision
Brain tumor excision under general anesthesia

Placebo Comparator: Control group

Brain tumor excision under general anesthesia. Intervention (Traditional fluid therapy): Control Group will receive standard fluid management of 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.

Procedure: Traditional fluid therapy
4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.

Procedure: Brain tumor excision
Brain tumor excision under general anesthesia

Outcome Measures

Primary Outcome Measures

  1. Evaluation of brain relaxation [one minute after dural puncture and one minute before dural closure]

    A 4-point scale will be performed as follows: grade 1, perfectly relaxed; grade 2, satisfactorily relaxed; grade 3, firm brain; grade 4, bulging brain.

Secondary Outcome Measures

  1. volume of intraoperative fluid requirements [intraoperatively]

    in litres

  2. Urine output [intraoperatively]

    Litres

  3. heart rate [intraoperatively]

    in beat per minute

  4. number of episodes of hypotension [intraoperatively]

    number of times where the blood pressure decreased by 25% of baseline

  5. arterial blood gases [one hour postoperatively]

    partial pressure of oxygen and carbon dioxide

  6. serum lactate [one hour postoperatively]

    in mmol per decilitre

  7. Hemoglobin concentration [one hour postoperatively]

    in grams per decilitre

  8. prothrombin concentration [one hour postoperatively]

    in percent

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients scheduled for supratentorial mass excision will be enrolled in the study.
Exclusion Criteria:
  • Patients with arrhythmias, pulmonary hypertension, impaired cardiac contractility, impaired liver or kidney function, and patients with BMI above 40 will be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cairo University Cairo Egypt

Sponsors and Collaborators

  • Cairo University

Investigators

  • Study Director: Ahmed Mukhtar, Professor, Head of research committee section in anesthesia department

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ahmed Hasanin, Lecturer of anesthesia and critical care medicine, Cairo University
ClinicalTrials.gov Identifier:
NCT03033706
Other Study ID Numbers:
  • MD-4-2016
First Posted:
Jan 27, 2017
Last Update Posted:
Nov 23, 2018
Last Verified:
Nov 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 23, 2018